ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D

• Appointment of Dr. Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, where he oversaw successful drug development for brands like Skyrizi, and Rinvoq
• Dr. Rob Scott brings extensive clinical development and regulatory experience to ABIONYX Pharma

Toulouse, FRANCE, Lakeland MI, USA, January 8, 2024, 6.00 p.m. CET - ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant apoA-I, is pleased to announce the appointment of Dr. Rob Scott as Chief Medical Officer and Head of R&D with immediate effect.
 
Cyrille Tupin, CEO of ABIONYX Pharma, commented: "We are excited to welcome Rob to our team just before the start of the J.P. Morgan Healthcare annual conference in San Francisco. As we develop our portfolio of clinical stage assets based on our unique apoA-I platform, Rob will bring us a wealth of experience to accelerate our programs. I look forward to working with Rob to transform ABIONYX Pharma into a successful biotech company focused on sepsis and other critical indications based on the only recombinant apoA-I in the industry."
 
Dr. Rob Scott commented: "I am delighted to be joining this next generation biotech, especially at a time of great momentum with the Company's latest outstanding Phase 2a results in sepsis. I look forward to working with the team to design and execute the pivotal approval program as ABIONYX continues to advance its exciting biodrug candidate through the clinical development and partnership process."
 
Dr. Scott brings extensive clinical development and regulatory experience to the company, having held senior leadership positions in global pharma and emerging biotech for over thirty years. Most recently, Dr. Scott retired as Chief Medical Officer at AbbVie, where he had responsibility for around 40 new molecular entities, four thousand people and a budget of around three billion dollars. During his tenure, Abbvie achieved over 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implement better clinical trials. In his previous roles at J&J, Pfizer and Amgen, Dr. Scott oversaw the development of blockbusters such as Lipitor, Norvasc, Caduet and Repatha.  Dr. Scott pioneered the conduct of large scale cardiovascular trials performed by emerging pharma during his time at Atherogenics with the ARISE Trial. Dr. Scott was a member of the FDA Cardiac and Renal Drug Advisory Committee and also served on the Endocrine & Metabolic Committee from 2012 to 2016.
 
Dr. Scott is currently on the boards of ArisGlobal, Confo Therapeutics, Draupnir Bio, Windtree Therapeutics, Redx Pharma, Oncospherix and Variant Bio as well as the scientific and strategic advisory boards of Variant Bio, Cytel, Inflexion, Orange Grove Bio and BioEthics International.